ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

House Committee Hits “Earmarks” For diseases; Broder Is Lectured On Occupational Exposures

May 21, 1993

In Brief: Biomedical Panel Report Will Support Cancer Program, Targeted Research

January 16, 1976

Why Shouldn’t Scientific Issues Be Discussed In Open Meetings? Editorial

November 10, 1989

BSA Eliminates Second Review For P01 Grants; R01Payline To increase to 24th Percentile

November 23, 1997

Randomization With Options Stimulates Sedmental Accrual

February 22, 1980

OSU Continues As comprehensive Center; City Of Hope BMT Program Wins 5-Year Grant.

July 14, 2000